BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

Fly fishing enthusiasts seeking a once-in-a-lifetime experience in untouched wilderness will soon have a new destination: the ...

William Blair analyst Dylan Becker maintained a Buy rating on Enfusion (ENFN – Research Report) today. The company’s shares opened today at $9.12. Becker covers the Technology sector, focusing on ...

Fintel reports that on October 30, 2024, William Blair downgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN) ...

However, for William “Will” Blair, it is his passion. Known for his relentless pursuit of untouched rivers and wilderness settings, Will has built a career and a lifestyle centered around ...

Altair Engineering (NASDAQ:ALTR – Free Report) had its price target boosted by Royal Bank of Canada from $90.00 to $113.00 in ...

William Blair downgraded Altair (ALTR) to Market Perform from Outperform without a price target after the company entered into a definitive ...

William Blair Small-Mid Cap Growth Fund earns a Below Average Process Pillar rating. The process is strengthened by its parent firm's long-term risk-adjusted performance, as shown by the firm's ...

Photo courtesy of Republic Services Inc. Chicago-based equities advisory firm William Blair has appointed equity research analyst Trevor Romeo to initiate coverage of three companies in the solid ...

Fintel reports that on September 18, 2024, William Blair initiated coverage of NVIDIA (WBAG:NVDA) with a Outperform recommendation. What is the Fund Sentiment? There are 6,506 funds or ...

Fintel reports that on October 30, 2024, William Blair downgraded their outlook for BioMarin Pharmaceutical (WBAG:BMRN) from Outperform to Market Perform. There are 1,150 funds or institutions ...